Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 15.58%80.04M | 43.27%24.34M | 7.63%18.69M | -82.33%69.25M | -93.67%17.72M | 17.18M | 16.99M | 17.37M | 391.83M | 279.76M |
Cost of revenue | 88.41M | |||||||||
Gross profit | 15.58%80.04M | 43.27%24.34M | 7.63%18.69M | -77.18%69.25M | -90.74%17.72M | 17.18M | 16.99M | 17.37M | 303.42M | 191.35M |
Operating expense | -6.27%897.92M | 27.54%222.49M | 7.12%187.28M | 31.31%958.01M | 22.01%286M | 322.73M | 174.46M | 174.83M | 729.58M | 234.41M |
Operating profit | 7.98%-817.88M | -25.84%-198.15M | -7.07%-168.59M | -108.55%-888.76M | -523.05%-268.27M | -305.55M | -157.47M | -157.47M | -426.17M | -43.06M |
Net non-operating interest income (expenses) | 102.61%189K | 11.47%-7.24M | -7.33M | 0 | -8.18M | 0 | ||||
Non-operating interest income | 114.77%189K | ---- | ---- | -57.49%88K | --0 | --0 | ---- | ---- | --207K | --0 |
Total other finance cost | ---- | ---- | ---- | -12.60%7.33M | ---- | ---- | ---- | ---- | --8.39M | --0 |
Net investment income | 143.88%717K | 2,969.64%1.61M | -11,722.22%-1.06M | -98.66%294K | -97.22%456K | -97K | -56K | -9K | 21.92M | 16.39M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | 44.05%62.01M | 0 | 544K | -47.55%43.05M | 0 | 42.95M | 82.08M | 2.05M | ||
Income before tax | 11.46%-754.96M | -24.80%-196.36M | -7.39%-169.11M | -158.12%-852.66M | -1,017.67%-275.15M | -262.7M | -157.34M | -157.48M | -330.34M | -24.62M |
Income tax | 0.07%1.49M | 0.27%374K | 0.00%372K | 0.00%1.49M | -0.27%372K | 373K | 373K | 372K | 1.49M | 373K |
Net income | 11.44%-756.45M | -24.74%-196.73M | -7.37%-169.49M | -157.41%-854.15M | -1,002.48%-275.52M | -263.07M | -157.71M | -157.85M | -331.83M | -24.99M |
Net income continuous operations | 11.44%-756.45M | -24.74%-196.73M | -7.37%-169.49M | -157.41%-854.15M | -1,002.47%-275.52M | ---263.08M | ---157.71M | ---157.85M | ---331.83M | ---24.99M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 11.44%-756.45M | -24.74%-196.73M | -7.37%-169.49M | -157.41%-854.15M | -1,002.48%-275.52M | -263.07M | -157.71M | -157.85M | -331.83M | -24.99M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 11.44%-756.45M | -24.74%-196.73M | -7.37%-169.49M | -157.41%-854.15M | -1,002.48%-275.52M | -263.07M | -157.71M | -157.85M | -331.83M | -24.99M |
Gross dividend payment | ||||||||||
Basic earnings per share | 25.40%-118.21 | -4.75%-30.68 | -0.65%-29.53 | -131.90%-158.46 | -1,441.09%-51.01 | -48.82 | -29.29 | -29.34 | -68.33 | -3.31 |
Diluted earnings per share | 25.40%-118.21 | -4.75%-30.68 | -0.65%-29.53 | -131.90%-158.46 | -998.26%-51.01 | -48.82 | -29.29 | -29.34 | -68.33 | -4.6446 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |